How we help
Our technology combines network analysis and data science to accurately measure brain function from fMRI data. We focus on how function relates to cognitive and socio-emotional diseases, including diseases that do not produce anatomical changes in the brain. This allows us to accurately judge whether a patient’s functional neural connectivity falls within ranges typical of a healthy individual or extent to which they deviate. Under repeat scanning, we can also measure the change in a patient’s neurological function with high accuracy. All of this lets us help you understand the efficacy of interventions with dramatically higher accuracy than is possible by interview and questionnaire — making it easier for you to get through clinical trials and into the market.
Many conditions affecting the brain do not produce anatomical changes and therefore cannot be observed directly with brain scanning technology. Examples include depression, anxiety, PTSD, early state-Alzheimers, mild to moderate traumatic injury, repeated sub-concusive injury, ADHD, autism and many more. As a result, the diagnosis and monitoring of these conditions is currently accomplished through questionnaires and structured interviews, which are coarse, subjective, qualitative, imprecise, and unreliable. This state of affairs makes it difficult to say, with a reasonable degree of accuracy, the extent of a patient’s cognitive and socio-emotional disruption. It also makes it difficult to judge the extent to which interventions are helpful in returning the patient to more normal brain function.
The Cerenetics solution
To solve this class of problems, we aim to create the first quantitative, objective, and direct measure of the cognitive and socio-emotional disruption that can result from brain illness or injury. Using fMRI, Cerenetics can measure — with mathematical accuracy and precision — changes in human neurological networks. We deliver a measure of the patient’s relevant brain function that is dramatically more accurate than qualitative questionnaires. The advantage offered by Cerenetics’ approach to data driven medicine over the current state of the art is akin to measuring a car’s speed by radar versus subjectively judging it to be going “fast” or “slow.”